Application of small molecular compound MLN4924 in resisting to HBV by combining with IFN[alpha]

A small molecular compound, the technology of MN4924, applied in the field of medicine, can solve the problems that have not been reported in clinical trials of tumor inhibitor MN4924, and achieve strong anti-HBV activity and strong drug effect

Inactive Publication Date: 2020-07-28
ZHEJIANG UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This compound is used as an important candidate antitumor drug by the National Cancer Institute (NCI) for phase I and I / III human clinical trials, but so far no clinical trials of the tumor inhibitor MN4924 on HBV have been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of small molecular compound MLN4924 in resisting to HBV by combining with IFN[alpha]
  • Application of small molecular compound MLN4924 in resisting to HBV by combining with IFN[alpha]
  • Application of small molecular compound MLN4924 in resisting to HBV by combining with IFN[alpha]

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] MLN4924 (250nM) was used to act on HepG2.2.15 cells. The control group was incubated with the cells in DMSO. After 48 hours, the cells of each group were collected and the cellular protein was extracted. Western blotting method found that MLN4924 can effectively inhibit HepG2.2.15 intracellular ubiquitin The expression of the molecule NEDD8 further prevents the activation of the Neddylation pathway. See the results figure 1 .

Embodiment 2

[0020] After taking different concentrations of IFNα (250U, 1000U) combined with MLN4924 (250nM), after 48 hours of treatment on HepG2.2.15 cells, the drug toxicity was detected by cck8 reagent (Dojindo Laboratories). The results showed that the cell survival rate was up to Both reached more than 80%, see the results figure 2 .

Embodiment 3

[0022] Different concentrations of IFNα (250U, 1000U) were combined with MLN4924 (250nM) to act on HepG2.2.15 cells. In the control group, 250U IFNα or 1000UIFNα or 250nM MLN4924 was used to incubate with the cells alone. The cell supernatant was collected after 48 hours and HBV was used. DNA detection kit (ACON Biotech Co. Ltd, Hangzhou, China) extracts HBV DNA from the supernatant and uses quantitative PCR (RT-qPCR) to detect HBV DNA titer. The results show that the inhibitory effect of IFNα and MLN4924 on HBVDNA is better than that of IFNα alone. See the results image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of small molecular compound MLN4924 in resisting to HBV by combining with IFN[alpha]. HepG2.2.15 cells capable of stably expressing HBV particles are used as a cell model, selection efficiency is high and toxicity is small; through the combination of the small molecular compound MLN4924 verified by many laboratories and clinical research and the IFN[alpha], cell Neddylation pathways can be blocked; and through experimental confirmation, the anti-tumor small molecular compound MLN4924 having good performance in clinical human trials has strong anti-HBV activity after combining with the IFN[alpha]. As the MLN4924 has long experience in prophase laboratory and clinical trials in the field of resisting to tumor and is strong in drug effects, so that the MLN4924 can be produced in large scale and has large potential to become efficient anti-HBV drugs. Thus, novel targets and research ideas can be established for the research of the anti-HBV drugs.

Description

Technical field [0001] The invention belongs to the field of medicine, and relates to the new use of the small molecule compound MLN4924, and in particular to the application of the combination of the small molecule compound MLN4924 and IFNα in the preparation of anti-hepatitis B virus (HBV) drugs. Background technique [0002] Hepatitis B virus (HBV) is a small, enveloped double-stranded DNA virus, belonging to the family of hepatoviridae. Chronic HBV infection (CHB) is still a major public health problem worldwide. Although the current hepatitis B vaccine is more effective in preventing and treating HBV infection, its coverage in areas with high endemicity of hepatitis B is still not satisfactory. According to statistics, about 250 million people worldwide have been infected with HBV, of which 75% are located in Asia and 12% are located in Africa. The risk of chronic HBV patients with liver cirrhosis, liver failure and liver cancer is about 15%-40%. Approximately 75,000 peop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61K31/519A61P31/20
CPCA61K31/519A61K38/212A61P31/20A61K2300/00
Inventor 郑敏谢明杰姚吉平
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap